The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.
Onto better TRAILs for cancer treatment
Open accessAbstract
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as Apo-2 ligand (Apo2L), is a member of the TNF cytokine superfamily. By cross-linking TRAIL-Receptor (TRAIL-R) 1 or TRAIL-R2, also known as death receptors 4 and 5 (DR4 and DR5), TRAIL has the capability to induce apoptosis in a wide variety of tumor cells while sparing vital normal cells. The discovery of this unique property among TNF superfamily members laid the foundation for testing the clinical potential of TRAIL-R-targeting therapies in the cancer clinic. To date, two of these therapeutic strategies have been tested clinically: (i) recombinant human TRAIL and (ii) antibodies directed against TRAIL-R1 or TRAIL-R2. Unfortunately, however, these TRAIL-R agonists have basically failed as most human tumors are resistant to apoptosis induction by them. It recently emerged that this is largely due to the poor agonistic activity of these agents. Consequently, novel TRAIL-R-targeting agents with increased bioactivity are currently being developed with the aim of rendering TRAIL-based therapies more active. This review summarizes these second-generation novel formulations of TRAIL and other TRAIL-R agonists, which exhibit enhanced cytotoxic capacity toward cancer cells, thereby providing the potential of being more effective when applied clinically than first-generation TRAIL-R agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Death-receptor activation halts clathrin-dependent endocytosis
Austin, C. D., Lawrence, D. A., Peden, A. A., Varfolomeev, E. E., Tótpál, K., Mazière, A. M. G. L. D., Klumperman, J., Arnott, D. P., Pham, V. C., Scheller, R. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604044103 · Cited by 116
RetractedMatsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis
Li, H., Zhu, H., Xu, C.-J., & Yuan, J. (1998) · Cell · doi:10.1016/s0092-8674(00)81590-1 · Cited by 4,445
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Luo, X., Budihardjo, I., Zou, H., Slaughter, C., & Wang, X. (1998) · Cell · doi:10.1016/s0092-8674(00)81589-5 · Cited by 3,626
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Inhibition of death receptor signals by cellular FLIP
Irmler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J.-L., Schröter, M., Burns, K., Mattmann, C., et al. (1997) · Nature · doi:10.1038/40657 · Cited by 2,563
Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., et al. (1999) · Nature Medicine · doi:10.1038/5517 · Cited by 2,497
Self-citationSafety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054
Tumor delivery of macromolecular drugs based on the EPR effect
Torchilin, V. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.011 · Cited by 2,032
Molecular mechanisms of caspase regulation during apoptosis
Riedl, S. J., & Shi, Y. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1496 · Cited by 1,899
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
The Receptor for the Cytotoxic Ligand TRAIL
Pan, G., O'Rourke, K., Chinnaiyan, A. M., Gentz, R., Ebner, R., Ni, J., & Dixit, V. M. (1997) · Science · doi:10.1126/science.276.5309.111 · Cited by 1,767
Catalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis
Oberst, A., Dillon, C. P., Weinlich, R., McCormick, L. L., Fitzgerald, P., Pop, C., Hakem, R., Salvesen, G. S., & Green, D. R. (2011) · Nature · doi:10.1038/nature09852 · Cited by 1,278
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c
Wei, M. C., Lindsten, T., Mootha, V. K., Weiler, S., Gross, A., Ashiya, M., Thompson, C. B., & Korsmeyer, S. J. (2000) · Genes & Development · doi:10.1101/gad.14.16.2060 · Cited by 1,268
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,184
Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
Maeda, H., Bharate, G. Y., & Daruwalla, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.11.010 · Cited by 1,168
TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL
Walczak, H. (1997) · The EMBO Journal · doi:10.1093/emboj/16.17.5386 · Cited by 1,130
Self-citationTumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
Maeda, H. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100070g · Cited by 998
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
Caspase activation: The induced-proximity model
Salvesen, G. S., & Dixit, V. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.20.10964 · Cited by 933
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Feoktistova, M., Geserick, P., Kellert, B., Dimitrova, D. P., Langlais, C., Hupe, M., Cain, K., MacFarlane, M., Häcker, G., & Leverkus, M. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.06.011 · Cited by 860
Jo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., & Goodwin, R. G. (1997) · Immunity · doi:10.1016/s1074-7613(00)80399-4 · Cited by 821
Schneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., & Tschopp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1205 · Cited by 812
Gastrosplenic Fistula From Hodgkin's Lymphoma
Seib, C. D., Rocha, F. G., Hwang, D. G., & Shoji, B. T. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7695 · Cited by 735
Chaudhary, P. M., Eby, M., Jasmin, A., Bookwalter, A., Murray, J., & Hood, L. (1997) · Immunity · doi:10.1016/s1074-7613(00)80400-8 · Cited by 711
Mechanisms of resistance to TRAIL-induced apoptosis in cancer
Zhang, L., & Fang, B. (2005) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700792 · Cited by 702
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
A novel receptor for Apo2L/TRAIL contains a truncated death domain
Marsters, S. A., Sheridan, J. P., Pitti, R. M., Huang, A., Skubatch, M., Baldwin, D., Yuan, J., Gurney, A., Goddard, A. D., Godowski, P., et al. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00422-2 · Cited by 653
TRAIL receptor-2 signals apoptosis through FADD and caspase-8
Bodmer, J.-L., Holler, N., Reynard, S., Vinciguerra, P., Schneider, P., Juo, P., Blenis, J., & Tschopp, J. (2000) · Nature Cell Biology · doi:10.1038/35008667 · Cited by 649
Evolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family
Degli-Esposti, M. A., Smolak, P. J., Walczak, H., Waugh, J., Huang, C.-P., DuBose, R. F., Goodwin, R. G., & Smith, C. A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1165 · Cited by 629
Self-citationWagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Totpal, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 612
The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting
Winkles, J. A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2488 · Cited by 601
Jin, Z., Li, Y., Pitti, R., Lawrence, D., Pham, V. C., Lill, J. R., & Ashkenazi, A. (2009) · Cell · doi:10.1016/j.cell.2009.03.015 · Cited by 591
Krueger, A., Schmitz, I., Baumann, S., Krammer, P. H., & Kirchhoff, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101780200 · Cited by 566
c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis
Chang, D. W. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf356 · Cited by 563
Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL
MacFarlane, M., Ahmad, M., Srinivasula, S. M., Fernandes-Alnemri, T., Cohen, G. M., & Alnemri, E. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25417 · Cited by 557
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Inhibition of Fas death signals by FLIPs
Tschopp, J., Irmler, M., & Thome, M. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80223-9 · Cited by 520
XIAP discriminates between type I and type II FAS-induced apoptosis
Jost, P. J., Grabow, S., Gray, D., McKenzie, M. D., Nachbur, U., Huang, D. C. S., Bouillet, P., Thomas, H. E., Borner, C., Silke, J., et al. (2009) · Nature · doi:10.1038/nature08229 · Cited by 482
The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex
Micheau, O., Thome, M., Schneider, P., Holler, N., Tschopp, J., Nicholson, D. W., Briand, C., & Grütter, M. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206882200 · Cited by 482
TRAIL signalling: Decisions between life and death
Falschlehner, C., Emmerich, C. H., Gerlach, B., & Walczak, H. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.02.007 · Cited by 458
Self-citationGetting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
Self-citationInitiator caspases in apoptosis signaling pathways
Chen, M., & Wang, J. (2002) · Apoptosis · doi:10.1023/a:1016167228059 · Cited by 449
Herbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O'Dwyer, P. J., Gordon, M. S., Novotny, W., Goldwasser, M. A., Tohnya, T. M., Lum, B. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1991 · Cited by 446
Kelley, S. K., Harris, L. A., Xie, D., DeForge, L., Totpal, K., Bussiere, J., & Fox, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29298-3 · Cited by 445
Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R. F., Ashkenazi, A., & de Vos, A. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80207-5 · Cited by 435
Holler, N., Tardivel, A., Kovacsovics-Bankowski, M., Hertig, S., Gaide, O., Martinon, F., Tinel, A., Deperthes, D., Calderara, S., Schulthess, T., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.4.1428-1440.2003 · Cited by 406
Membrane-bound Fas ligand only is essential for Fas-induced apoptosis
O’ Reilly, L. A., Tai, L., Lee, L., Kruse, E. A., Grabow, S., Fairlie, W. D., Haynes, N. M., Tarlinton, D. M., Zhang, J.-G., Belz, G. T., et al. (2009) · Nature · doi:10.1038/nature08402 · Cited by 400
The Fas–FADD death domain complex structure unravels signalling by receptor clustering
Scott, F. L., Stec, B., Pop, C., Dobaczewska, M. K., Lee, J. J., Monosov, E., Robinson, H., Salvesen, G. S., Schwarzenbacher, R., & Riedl, S. J. (2009) · Nature · doi:10.1038/nature07606 · Cited by 384
Targeting death receptors in cancer with Apo2L/TRAIL
KELLEY, S. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.02.006 · Cited by 370
Dickens, L. S., Boyd, R. S., Jukes-Jones, R., Hughes, M. A., Robinson, G. L., Fairall, L., Schwabe, J. W. R., Cain, K., & MacFarlane, M. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.004 · Cited by 349
Expression and Function of TNF-Related Apoptosis-Inducing Ligand on Murine Activated NK Cells
Kayagaki, N., Yamaguchi, N., Nakayama, M., Takeda, K., Akiba, H., Tsutsui, H., Okamura, H., Nakanishi, K., Okumura, K., & Yagita, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.1906 · Cited by 340
Ke, W., Shao, K., Huang, R., Han, L., Liu, Y., Li, J., Kuang, Y., Ye, L., Lou, J., & Jiang, C. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.08.049 · Cited by 337
MAPK/ERK Overrides the Apoptotic Signaling from Fas, TNF, and TRAIL Receptors
Tran, S. E. F., Holmström, T. H., Ahonen, M., Kähäri, V.-M., & Eriksson, J. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010384200 · Cited by 330
TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL
Screaton, G. R., Mongkolsapaya, J., Xu, X.-N., Cowper, A. E., McMichael, A. J., & Bell, J. I. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00297-1 · Cited by 325
Apoptosis-inducing factor: vital and lethal
Modjtahedi, N., Giordanetto, F., Madeo, F., & Kroemer, G. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.03.008 · Cited by 323
Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2
Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, E., & Micheau, O. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00520-06 · Cited by 305
Characterization of two receptors for TRAIL1
Schneider, P., Bodmer, J.-L., Thome, M., Hofmann, K., Holler, N., & Tschopp, J. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01231-3 · Cited by 290
Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., DeForge, L., Pai, R., Hymowitz, S. G., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410660200 · Cited by 284
Varfolomeev, E., Maecker, H., Sharp, D., Lawrence, D., Renz, M., Vucic, D., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509560200 · Cited by 282
Dhein, J., Daniel, P. T., Trauth, B. C., Oehm, A., Möller, P., & Krammer, P. H. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.10.3166 · Cited by 278
Dimberg, L. Y., Anderson, C. K., Camidge, R., Behbakht, K., Thorburn, A., & Ford, H. L. (2013) · Oncogene · doi:10.1038/onc.2012.164 · Cited by 276
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam, D., Szegezdi, E., Keane, M., Jong, S. D., & Samali, A. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.006 · Cited by 272
A Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL
Hymowitz, S. G., O'Connell, M. P., Ultsch, M. H., Hurst, A., Totpal, K., Ashkenazi, A., de Vos, A. M., & Kelley, R. F. (2000) · Biochemistry · doi:10.1021/bi992242l · Cited by 261
Holcik, M., & Korneluk, R. G. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35080103 · Cited by 251
Wilson, N. S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.012 · Cited by 248
Soria, J.-C., Márk, Z., Zatloukal, P., Szima, B., Albert, I., Juhász, E., Pujol, J.-L., Kozielski, J., Baker, N., Smethurst, D., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2623 · Cited by 246
Activation of caspases-8 and -10 by FLIPL
BOATRIGHT, K. M., DEIS, C., DENAULT, J.-B., SUTHERLIN, D. P., & SALVESEN, G. S. (2004) · Biochemical Journal · doi:10.1042/bj20040809 · Cited by 245
Temperature-sensitive Differential Affinity of TRAIL for Its Receptors
Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., Mclaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910438199 · Cited by 245
Defining Characteristics of Types I and II Apoptotic Cells in Response to TRAIL
Özören, N., & El-Deiry, W. S. (2002) · Neoplasia · doi:10.1038/sj.neo.7900270 · Cited by 237
Bae, S., Ma, K., Kim, T. H., Lee, E. S., Oh, K. T., Park, E.-S., Lee, K. C., & Youn, Y. S. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.050 · Cited by 236
Cell death induction by receptors of the TNF family: towards a molecular understanding
Wallach, D., Boldin, M., Varfolomeev, E., Beyaert, R., Vandenabeele, P., & Fiers, W. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00553-x · Cited by 233
Clancy, L., Mruk, K., Archer, K., Woelfel, M., Mongkolsapaya, J., Screaton, G., Lenardo, M. J., & Chan, F. K.-M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507329102 · Cited by 232
FADD Is Required for DR4- and DR5-mediated Apoptosis
Kuang, A. A., Diehl, G. E., Zhang, J., & Winoto, A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.c000284200 · Cited by 232
Involvement of TNF-Related Apoptosis-Inducing Ligand in Human CD4+ T Cell-Mediated Cytotoxicity
Kayagaki, N., Yamaguchi, N., Nakayama, M., Kawasaki, A., Akiba, H., Okumura, K., & Yagita, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2639 · Cited by 231
Soria, J.-C., Smit, E., Khayat, D., Besse, B., Yang, X., Hsu, C.-P., Reese, D., Wiezorek, J., & Blackhall, F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4847 · Cited by 231
Pop, C., Oberst, A., Drag, M., Van Raam, B. J., Riedl, S. J., Green, D. R., & Salvesen, G. S. (2011) · Biochemical Journal · doi:10.1042/bj20101738 · Cited by 226
Lin, Y., Devin, A., Cook, A., Keane, M. M., Kelliher, M., Lipkowitz, S., & Liu, Z.-G. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.18.6638-6645.2000 · Cited by 222
TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma
Trauzold, A., Siegmund, D., Schniewind, B., Sipos, B., Egberts, J., Zorenkov, D., Emme, D., Röder, C., Kalthoff, H., & Wajant, H. (2006) · Oncogene · doi:10.1038/sj.onc.1209719 · Cited by 219
Ganten, T. M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Büchler, P., Haas, T. L., Schader, M. B., Untergasser, A., Stremmel, W., & Walczak, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2635 · Cited by 217
Self-citationTRAIL-coated leukocytes that kill cancer cells in the circulation
Mitchell, M. J., Wayne, E., Rana, K., Schaffer, C. B., & King, M. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316312111 · Cited by 213
Wajant, H., Moosmayer, D., Wüest, T., Bartke, T., Gerlach, E., Schönherr, U., Peters, N., Scheurich, P., & Pfizenmaier, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204558 · Cited by 212
The ‘complexities’ of life and death: Death receptor signalling platforms
Dickens, L. S., Powley, I. R., Hughes, M. A., & MacFarlane, M. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.04.005 · Cited by 208
Development of liposomal formulations: From concept to clinical investigations
Fan, Y., & Zhang, Q. (2013) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2013.07.010 · Cited by 206
EPR-effect: Utilizing size-dependent Nanoparticle Delivery to Solid Tumors
Stylianopoulos, T. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.8 · Cited by 197
Ganten, T. M., Haas, T. L., Sykora, J., Stahl, H., Sprick, M. R., Fas, S. C., Krueger, A., Weigand, M. A., Grosse-Wilde, A., Stremmel, W., et al. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401437 · Cited by 196
Self-citationvon Karstedt, S., Conti, A., Nobis, M., Montinaro, A., Hartwig, T., Lemke, J., Legler, K., Annewanter, F., Campbell, A. D., Taraborrelli, L., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.014 · Cited by 196
Self-citationThe promise of TRAIL—potential and risks of a novel anticancer therapy
Koschny, R., Walczak, H., & Ganten, T. M. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0194-1 · Cited by 195
Self-citationDeath receptors as targets in cancer
Micheau, O., Shirley, S., & Dufour, F. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12238 · Cited by 189
The Structure of FADD and Its Mode of Interaction with Procaspase-8
Carrington, P. E., Sandu, C., Wei, Y., Hill, J. M., Morisawa, G., Huang, T., Gavathiotis, E., Wei, Y., & Werner, M. H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.04.018 · Cited by 188
Martínez-Lorenzo, M. J., Alava, M. A., Gamen, S., Kim, K. J., Chuntharapai, A., Piñeiro, A., Naval, J., & Anel, A. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199809)28:09<2714::aid-immu2714>3.0.co;2-9 · Cited by 183
Self-citationMax, R., Gerritsen, R. R. C. M., Nooijen, P. T. G. A., Goodman, S. L., Sutter, A., Keilholz, U., Ruiter, D. J., & De Waal, R. M. W. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970502)71:3<320::aid-ijc2>3.0.co;2-# · Cited by 175
Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting
Kortt, A. A., Dolezal, O., Power, B. E., & Hudson, P. J. (2001) · Biomolecular Engineering · doi:10.1016/s1389-0344(01)00090-9 · Cited by 173
Morel, J., Audo, R., Hahne, M., & Combe, B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414469200 · Cited by 172
Kruyt, F. A. E. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.003 · Cited by 172
van der Sloot, A. M., Tur, V., Szegezdi, E., Mullally, M. M., Cool, R. H., Samali, A., Serrano, L., & Quax, W. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510187103 · Cited by 169
TRAIL Receptor-Selective Mutants Signal to Apoptosis via TRAIL-R1 in Primary Lymphoid Malignancies
MacFarlane, M., Kohlhaas, S. L., Sutcliffe, M. J., Dyer, M. J. S., & Cohen, G. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2801 · Cited by 163
tBID Homooligomerizes in the Mitochondrial Membrane to Induce Apoptosis
Grinberg, M., Sarig, R., Zaltsman, Y., Frumkin, D., Grammatikakis, N., Reuveny, E., & Gross, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104893200 · Cited by 161
Graves, J. D., Kordich, J. J., Huang, T.-H., Piasecki, J., Bush, T. L., Sullivan, T., Foltz, I. N., Chang, W., Douangpanya, H., Dang, T., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.028 · Cited by 161
Wyzgol, A., Müller, N., Fick, A., Münkel, S., Grigoleit, G. U., Pfizenmaier, K., & Wajant, H. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802597 · Cited by 159
TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them
Thorburn, A., Behbakht, K., & Ford, H. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.02.001 · Cited by 158
2.8 Å Resolution Crystal Structure of Human TRAIL, a Cytokine with Selective Antitumor Activity
Cha, S.-S., Kim, M.-S., Choi, Y. H., Sung, B.-J., Shin, N. K., Shin, H.-C., Sung, Y. C., & Oh, B.-H. (1999) · Immunity · doi:10.1016/s1074-7613(00)80100-4 · Cited by 158
Protective Roles for Caspase-8 and cFLIP in Adult Homeostasis
Weinlich, R., Oberst, A., Dillon, C. P., Janke, L. J., Milasta, S., Lukens, J. R., Rodriguez, D. A., Gurung, P., Savage, C., Kanneganti, T. D., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.045 · Cited by 157
Burns, T. F., & El‐Deiry, W. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103516200 · Cited by 157
Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer
Choi, S. H., Byeon, H. J., Choi, J. S., Thao, L., Kim, I., Lee, E. S., Shin, B. S., Lee, K. C., & Youn, Y. S. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.008 · Cited by 156
Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1
MacFarlane, M., Inoue, S., Kohlhaas, S. L., Majid, A., Harper, N. W., Kennedy, D. B., Dyer, M. J. S., & Cohen, G. M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401649 · Cited by 156
Mühlenbeck, F., Schneider, P., Bodmer, J.-L., Schwenzer, R., Hauser, A., Schubert, G., Scheurich, P., Moosmayer, D., Tschopp, J., & Wajant, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000482200 · Cited by 153
Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis
Joy, A. M., Beaudry, C. E., Tran, N. L., Ponce, F. A., Holz, D. R., Demuth, T., & Berens, M. E. (2003) · Journal of Cell Science · doi:10.1242/jcs.00712 · Cited by 153
Adams, C., Totpal, K., Lawrence, D., Marsters, S., Pitti, R., Yee, S., Ross, S., Deforge, L., Koeppen, H., Sagolla, M., et al. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402306 · Cited by 148
Hoogwater, F. J. H., Nijkamp, M. W., Smakman, N., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.046 · Cited by 147
TRAIL Inhibits Tumor Growth but Is Nontoxic to Human Hepatocytes in Chimeric Mice
Hao, C., Song, J. H., Hsi, B., Lewis, J. T., Song, D. K., Petruk, K. C., Tyrrell, D., & Kneteman, N. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2599 · Cited by 147
Sun, X., Pang, Z., Ye, H., Qiu, B., Guo, L., Li, J., Ren, J., Qian, Y. J., Zhang, Q., Chen, J., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.10.035 · Cited by 139
Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors.
Spierings, D. C. J., de Vries, E. G. E., Timens, W., Groen, H. J. M., Boezen, H. M., & de Jong, S. (2003) · PubMed · Cited by 138
Is TRAIL the holy grail of cancer therapy?
Newsom-Davis, T. E., Prieske, S., & Walczak, H. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0321-2 · Cited by 137
Self-citationBratton, S. B., Lewis, J., Butterworth, M., Duckett, C. S., & Cohen, G. M. (2002) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401069 · Cited by 131
Sträter, J., Hinz, U., Walczak, H., Mechtersheimer, G., Koretz, K., Herfarth, C. H., Möller, P., & Lehnert, T. (2002) · PubMed · Cited by 131
Self-citationBerg, D., Lehne, M., Müller, N., Siegmund, D., Münkel, S., Sebald, W., Pfizenmaier, K., & Wajant, H. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402213 · Cited by 130
Şanlioğlu, A. D., Dirice, E., Aydın, Ç., Erin, N., Köksoy, S., & Şanlıoğlu, S. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-54 · Cited by 129
Mellier, G., Huang, S., Shenoy, K., & Pervaiz, S. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.12.002 · Cited by 124
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
Lemke, J., von Karstedt, S., Hay, M. Y. A. E., Conti, A., Vargas, F. A., Montinaro, A., Papenfuss, K., El-Bahrawy, M. A., & Walczak, H. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.179 · Cited by 124
Self-citationGieffers, C., Kluge, M., Merz, C., Sykora, J., Thiemann, M., Schaal, R., Fischer, C., Branschädel, M., Abhari, B. A., Hohenberger, P., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0323 · Cited by 121
Voortman, J., Resende, T. P., Hassan, M., Giaccone, G., & Kruyt, F. A. E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0167 · Cited by 116
Koschny, R., Ganten, T. M., Sykora, J., Haas, T. L., Sprick, M. R., Kolb, A., Stremmel, W., & Walczak, H. (2007) · Hepatology · doi:10.1002/hep.21555 · Cited by 115
Self-citationA Role of the Mitochondrial Apoptosis-Inducing Factor in Granulysin-Induced Apoptosis
Pardo, J., Pérez‐Galán, P., Gamen, S., Marzo, I., Monleón, I., Kaspar, A. A., Susín, S. A., Kroemer, G., Krensky, A. M., Naval, J., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1222 · Cited by 113
Self-citationPalacios, C., Yerbes, R., & López‐Rivas, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0808 · Cited by 106
Geserick, P., Drewniok, C., Hupe, M., Haas, T. L., Diessenbacher, P., Sprick, M. R., Schön, M. P., Henkler, F., Gollnick, H. P. M., Walczak, H., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210985 · Cited by 105
Self-citationLiposome‐bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis
Martínez‐Lostao, L., Garcí´a‐Alvarez, F., Basáñez, G., Alegre‐Aguarón, E., Desportes, P., Larrad, L., Naval, J., Martínez‐Lorenzo, M. J., & Anel, A. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27501 · Cited by 100
Self-citationDeath receptor agonist therapies for cancer, which is the right TRAIL?
Holland, P. M. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.12.009 · Cited by 100
TRAIL treatment provokes mutations in surviving cells
Lovric, M. M., & Hawkins, C. J. (2010) · Oncogene · doi:10.1038/onc.2010.242 · Cited by 98
Proliferative versus apoptotic functions of caspase-8
van Raam, B. J., & Salvesen, G. S. (2011) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.06.005 · Cited by 90
Type I and type II reactions in TRAIL-induced apoptosis – results from dose–response studies
Rudner, J., Jendrossek, V., Lauber, K., Daniel, P. T., Wesselborg, S., & Belka, C. (2004) · Oncogene · doi:10.1038/sj.onc.1208191 · Cited by 90
Sträter, J., Walczak, H., Pukrop, T., von Müller, L., Hasel, C., Kornmann, M., Mertens, T., & Möller, P. (2002) · Gastroenterology · doi:10.1053/gast.2002.31889 · Cited by 87
Self-citationChemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level
Morizot, A., Mérino, D., Lalaoui, N., Jacquemin, G., Granci, V., Iessi, E., Lanneau, D., Bouyer, F., Solary, É., Chauffert, B., et al. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.144 · Cited by 82
Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells
de Miguel, D., Basáñez, G., Sánchez‐Martínez, D., Galán‐Malo, P., Marzo, I., Larrad, L., Naval, J., Pardo, J., Anel, A., & Martínez‐Lostao, L. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300258c · Cited by 81
Self-citationLemke, J., Noack, A., Adam, D., Tchikov, V., Bertsch, U., Röder, C., Schütze, S., Wajant, H., Kalthoff, H., & Trauzold, A. (2010) · Journal of Molecular Medicine · doi:10.1007/s00109-010-0619-0 · Cited by 81
Self-citationEnhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display
Nair, P. M., Flores, H., Gogineni, A., Marsters, S. A., Lawrence, D. A., Kelley, R. F., Ngu, H., Sagolla, M. S., Kömüves, L. G., Bourgon, R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418962112 · Cited by 80
Lim, S. M., Kim, T. H., Jiang, H. H., Park, C. W., Lee, S., Chen, X. S., & Lee, K. C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.054 · Cited by 80
Hallermalm, K., Geer, A. D., Kiessling, R. W., Levitsky, V., & Levitskaya, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0508 · Cited by 79
Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection
Yee, J., Sadar, M. D., Sin, D. D., Kuzyk, M. A., Xing, L., Kondra, J., McWilliams, A. M., Man, S. F. P., & Lam, S. C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4233 · Cited by 79
Superior serum half life of albumin tagged TNF ligands
Müller, N., Schneider, B., Pfizenmaier, K., & Wajant, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.134 · Cited by 76
Chae, S. Y., Kim, T. H., Park, K., Jin, C., Son, S., Lee, S., Youn, Y. S., Kim, K., Jo, D., Kwon, I. C., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1076 · Cited by 76
Guo, L., Fan, L., Pang, Z., Ren, J., Ren, Y., Li, J., Chen, J., Wen, Z., & Jiang, X. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.05.008 · Cited by 75
de Bruyn, M., Rybczynska, A. A., Wei, Y., Schwenkert, M., Fey, G. H., Dierckx, R., van Waarde, A., Helfrich, W., & Bremer, E. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-301 · Cited by 75
Reis, C. R., van der Sloot, A. M., Natoni, A., Szegezdi, É., Setroikromo, R., Meijer, M., Sjollema, K. A., Stricher, F., Cool, R. H., Samali, A., et al. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.61 · Cited by 74
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
Tuthill, M. H., Montinaro, A., Zinngrebe, J., Prieske, K., Dráber, P., Prieske, S., Newsom-Davis, T. E., von Karstedt, S., Graves, J. D., & Walczak, H. (2014) · Oncogene · doi:10.1038/onc.2014.156 · Cited by 74
Self-citationKurbanov, B. M., Geilen, C. C., Fecker, L. F., Orfanos, C. E., & Eberle, J. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23900.x · Cited by 74
Riley, J. S., Hutchinson, R. A., McArt, D. G., Crawford, N., Holohan, C., Paul, I., Schaeybroeck, S. V., Salto‐Tellez, M., Johnston, P. G., Fennell, D. A., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.481 · Cited by 73
Schneider, B., Münkel, S., Krippner‐Heidenreich, A., Grunwald, I., Wels, W. S., Wajant, H., Pfizenmaier, K., & Gerspach, J. (2010) · Cell Death and Disease · doi:10.1038/cddis.2010.45 · Cited by 73
Yan, C., Li, S., Li, Z., Peng, H., Yuan, X., Jiang, L., Zhang, Y., Fan, D., Hu, X., Yang, M., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300261e · Cited by 71
Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature
Cao, L., Du, P., Jiang, S.-H., Jin, G., Huang, Q.-L., & Hua, Z. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0533 · Cited by 71
Perlstein, B., Finniss, S., Miller, C. G., Okhrimenko, H., Kazimirsky, G., Cazacu, S., Lee, H. K., Lemke, N. W., Brodie, S., Umansky, F., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos248 · Cited by 71
Xiang, H., Nguyen, C. B., Kelley, S. K., Dybdal, N. O., & Escandón, E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000323 · Cited by 70
Yee, L., Fanale, M. A., Dimick, K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8078 · Cited by 68
Tur, V., van der Sloot, A. M., Reis, C. R., Szegezdi, É., Cool, R. H., Samali, A., Serrano, L., & Quax, W. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800457200 · Cited by 67
The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL
Grunert, M., Gottschalk, K., Kapahnke, J., Gündisch, S., Kieser, A., & Jeremias, I. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.154 · Cited by 64
ten Cate, B., Bremer, E., de Bruyn, M., Bijma, T., Samplonius, D. F., Schwemmlein, M., Huls, G. A., Fey, G. H., & Helfrich, W. (2009) · Leukemia · doi:10.1038/leu.2009.34 · Cited by 63
Stieglmaier, J., Bremer, E., Kellner, C., Liebig, T. M., ten Cate, B., Peipp, M., Schulze‐Koops, H., Pfeiffer, M. M., Bühring, H., Greil, J., et al. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0370-8 · Cited by 62
Gómez‐Benito, M. J., Martínez‐Lorenzo, M. J., Anel, A., Marzo, I., & Naval, J. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.03.018 · Cited by 60
Self-citationWainberg, Z. A., Messersmith, W. A., Peddi, P. F., Kapp, A. V., Ashkenazi, A., Royer‐Joo, S., Portera, C. C., & Kozloff, M. F. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.06.002 · Cited by 60
Şanlioğlu, A. D., Korcum, A. F., Peştereli, E., Erdoğan, G., Karaveli, Ş., Savaş, B., Griffith, T. S., & Şanlıoğlu, S. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.03.057 · Cited by 56
Lee, H.-M., Timme, T. L., & Thompson, T. C. (2000) · PubMed · Cited by 55
Clinical uses of pegylated pharmaceuticals in oncology
Crawford, J. (2002) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(02)80003-2 · Cited by 54
Kim, T. H., Jiang, H. H., Park, C. W., Youn, Y. S., Lee, S., Chen, X. S., & Lee, K. C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.10.037 · Cited by 52
Antibody-based fusion proteins to target death receptors in cancer
de Bruyn, M., Bremer, E., & Helfrich, W. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.11.006 · Cited by 52
PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy
Jiang, H. H., Kim, T. H., Lee, S., Chen, X. S., Youn, Y. S., & Lee, K. C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.07.051 · Cited by 50
Azijli, K., Yuvaraj, S., van Roosmalen, I. A. M., Flach, K. D., Giovannetti, E., Peters, G. J., de Jong, S., & Kruyt, F. A. E. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0829-3 · Cited by 49
de Miguel, D., Gallego-Lleyda, A., Anel, A., & Martínez‐Lostao, L. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.03.019 · Cited by 49
Self-citationWahl, K., Siegemund, M., Lehner, F., Vondran, F. W. R., Nussler, A. K., Länger, F. P., Krech, T., Kontermann, R. E., Manns, M. P., Schulze‐Osthoff, K., et al. (2012) · Hepatology · doi:10.1002/hep.26082 · Cited by 48
Kim, T. H., Jiang, H., Youn, Y. S., Park, C. W., Lim, S. M., Jin, C., Tak, K. K., Lee, H. S., & Lee, K. C. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22298 · Cited by 45
Tumor-targeted delivery of biologically active TRAIL protein
Zhang, H.-Y., Man, J.-H., Liang, B., Zhou, T., Wang, C., Li, T., Li, H.-Y., Li, W. H., Jin, B.-F., Zhang, P.-J., et al. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2009.76 · Cited by 43
Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells
Rozanov, D. V., Savinov, A. Y., Golubkov, V. S., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0202 · Cited by 43
Immuno-LipoTRAIL: Targeted Delivery of TRAIL-Functionalized Liposomal Nanoparticles
Seifert, O., Pollak, N., Nusser, A., Steiniger, F., Rüger, R., Pfizenmaier, K., & Kontermann, R. E. (2014) · Bioconjugate Chemistry · doi:10.1021/bc400517j · Cited by 42
Jiang, X. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s24711 · Cited by 40
Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells
de Bruyn, M., Wei, Y., Wiersma, V. R., Samplonius, D. F., Klip, H. G., van der Zee, A. G. J., Yang, B., Helfrich, W., & Bremer, E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0303 · Cited by 36
Otten, H. G., van Ginkel, W. G. J., Hagenbeek, A., & Petersen, E. J. (2004) · Leukemia · doi:10.1038/sj.leu.2403414 · Cited by 34
de Miguel, D., Gallego-Lleyda, A., Galán‐Malo, P., Rodríguez‐Vigil, C., Marzo, I., Anel, A., & Martínez‐Lostao, L. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1295-x · Cited by 32
Self-citationEl‐Mesery, M., Trebing, J., Schäfer, V., Weisenberger, D., Siegmund, D., & Wajant, H. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.402 · Cited by 32
Razmara, M., Hilliard, B. A., Ziarani, A. K., Murali, R., Yellayi, S., Ghazanfar, M., Chen, Y. H., & Tykocinski, M. L. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080462 · Cited by 32
Mühlethaler‐Mottet, A., Flahaut, M., Bourloud, K. B., Nardou, K., Coulon, A., Liberman, J., Thome, M., & Gross, N. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.8 · Cited by 31
Yee, L., Burris, H. A., Kozloff, M. F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4129 · Cited by 31
Bremer, E., de Bruyn, M., Samplonius, D. F., Bijma, T., ten Cate, B., de Leij, L. F. M. H., & Helfrich, W. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0348-9 · Cited by 30
Loi, M., Becherini, P., Emionite, L., Giacomini, A., Cossu, I., Destefanis, E., Brignole, C., Paolo, D. D., Piaggio, F., Perri, P., et al. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.009 · Cited by 30
Liposomes as Carriers of Anticancer Drugs
Lopes, S. C. D. A., Giuberti, C. D. S., Ribeiro, T. G., Ferreira, D. D. S., Leite, E. A., & Cristina, M. (2013) · InTech eBooks · doi:10.5772/55290 · Cited by 27
Targeting disease by immunomodulation
Kaufmann, T., & Simon, H. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2014.166 · Cited by 25
Targeting AML through DR4 with a novel variant of rhTRAIL
Szegezdi, É., Reis, C. R., van der Sloot, A. M., Natoni, A., O’Reilly, A., Reeve, J. L., Cool, R. H., O'Dwyer, M. E., Knapper, S., Serrano, L., et al. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01211.x · Cited by 25
Kim, H., Jeong, D., Kang, H. E., Lee, K. C., & Na, K. (2012) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2012.01564.x · Cited by 24
Tumor resistance to specific lysis: A major hurdle for successful immunotherapy of cancer
Chouaı̈b, S., Meslin, F., Thiery, J., & Mami‐Chouaib, F. (2008) · Clinical Immunology · doi:10.1016/j.clim.2008.08.020 · Cited by 15
Kasubhai, S. M., Bendell, J. C., Kozloff, M. F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.3543 · Cited by 14
Cited by
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals
Folkersen, L., Gustafsson, S., Wang, Q., Hansen, D. H., Hedman, Å. K., Schork, A., Page, K., Zhernakova, D. V., Wu, Y., Peters, J., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00287-2 · Cited by 705
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556
Self-citationProgrammed Cell Death Tunes Tumor Immunity
Liu, J., Hong, M., Li, Y., Chen, D., Wu, Y., & Hu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.847345 · Cited by 316
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
Metadata
- Authors
- de Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martinez-Lostao, L.
- Venue
- Cell Death & Differentiation
- Published
- 2016-03-04
- Volume
- 23
- Issue
- 5
- Pages
- 733-747
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W2290145688
- Cited by
- 304
- References
- 195
- FWCI
- 21.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.